Ethics in Practice: Immunotherapy at End of Life in Head and Neck Cancer

Mr R is a 65-year-old man with recurrent, unresectable mucosal squamous cell carcinoma of the head and neck. Two years earlier, biopsy confirmed locally advanced disease, and definitive chemoradiation was recommended. After extensive counseling, he declined curative-intent therapy because of concerns about treatment-related toxicity and impact on quality of life. Over time, his disease progressed. He now presents with bulky locoregional tumor burden associated with pain, dysphagia, weight loss, and declining functional status. Imaging demonstrates extensive soft tissue invasion without evidence of distant metastases or acute oncologic catastrophe. His performance status is poor (ECOG 2-3), and prognosis is limited. At multidisciplinary tumor board discussion, management options are revisited. One approach is to offer systemic therapy, including immunotherapy consistent with current standards for recurrent or unresectable disease, recognizing the low likelihood of meaningful benefit given his functional status and limited life expectancy. An alternative approach is to recommend exclusive comfort-focused palliative care, emphasizing symptom control and quality of life. When prognosis is poor and anticipated benefit is marginal, should clinicians offer disease-directed systemic therapy, or recommend guideline-concordant palliation alone? Advances in systemic therapy, particularly immune checkpoint inhibition, have altered the therapeutic landscape for patients with recurrent or unresectable head and neck squamous cell carcinoma (HNSCC).1 While evidence-based guidelines appropriately anchor oncologic decision-making, they cannot fully anticipate the ethical complexity that arises when prognosis is limited, functional status is poor, and patient goals are evolving. In such circumstances, the ethical question is not whether immunotherapy is guideline-supported, but whether it should be offered or recommended when anticipated benefit is marginal and risks are substantial. Respect for patient autonomy requires that clinicians present medically reasonable options in a manner that allows informed, values-based decision-making. 7, patients retain the right to reconsider earlier decisions as disease progresses and circumstances change. Autonomy is not static; it is exercised over time and must be reassessed in light of new clinical realities. Offering systemic therapy as one possible option, without presumption of benefit, permits the patient to engage meaningfully in decisions about the balance between potential disease control, symptom burden, and quality of life. Importantly, honoring autonomy does not obligate clinicians to recommend aggressive treatment, but it does require transparency about available options and their realistic implications. Immunotherapy is an accepted standard of care for recurrent or unresectable mucosal HNSCC, with durable responses observed in a minority of patients. While the likelihood of meaningful benefit decreases substantially in patients with poor performance status and limited life expectancy, it is not uniformly zero.2, 3 Ethical justification for offering therapy in this context rests on proportionality; whether the potential benefits, however small, are reasonably balanced against anticipated harms. In carefully selected cases, a time-limited trial of systemic therapy may be ethically defensible when framed explicitly as non-curative, closely monitored, and contingent on early clinical tolerance and response. Such an approach avoids therapeutic absolutism while maintaining clinical humility regarding uncertain outcomes. If systemic therapy is offered, it must occur within a robust shared decision-making framework. This includes explicit discussion of low response probability, delayed onset of benefit, potential toxicities, and the possibility that treatment may not improve, and could worsen, quality of life. 2,3 Clear stopping rules should be established in advance, and palliative care should be integrated concurrently rather than deferred. In this setting, informed consent is not merely procedural but ethical. It safeguards against therapeutic misconception and ensures that patient expectations remain aligned with clinical reality. Ethical deliberation must also consider justice and equity. Access to immunotherapy is influenced by insurance coverage, socioeconomic status, health literacy, and institutional resources. For some patients, the opportunity to consider systemic therapy may be shaped as much by structural barriers as by clinical appropriateness. Ensuring that decisions are guided by patient goals and clinical proportionality, rather than by implicit rationing or institutional norms, supports equitable care, even when the ultimate recommendation is palliation. Oncologic standards evolve continuously, often informed by real-world clinical experience at the margins of guideline-defined populations. Ethical practice does not require rigid adherence to protocols when patient circumstances fall outside the populations studied in clinical trials. Rather, it demands careful application of evidence, tempered by clinical judgment and patient values. In rare cases, ethical responsibility may include offering therapy while acknowledging uncertainty, rather than foreclosing options based solely on prognosis. In patients with advanced HNSCC, poor performance status, and limited life expectancy, offering systemic therapy may be ethically defensible when framed as a proportional, time-limited option grounded in transparent communication and shared decision-making. Such an approach respects autonomy without promoting false hope, preserves beneficence without ignoring harm, and allows palliative priorities to remain central. Ethical care in this context lies not in the intervention itself, but in how, and why, it is offered. While the impulse to pursue disease-directed therapy is understandable, ethical medical practice requires proportionality grounded in evidence, compassion, and realism. In patients with advanced HNSCC, poor performance status, and limited life expectancy, the most ethically defensible course may be a recommendation for comfort-focused, guideline-concordant palliation rather than escalation of systemic therapy. Chemotherapy and immunotherapy carry well-documented risks, including cytopenias, infections, mucositis, fatigue, and immune-mediated toxicities.4 In patients with limited physiologic reserve, these harms may be immediate and substantial, while the likelihood of clinical benefit is low. Immune checkpoint inhibitors often require weeks to months to demonstrate response, a timeframe that may exceed the patient's anticipated survival or functional tolerance.5 In such cases, initiating systemic therapy risks exacerbating suffering, prolonging hospitalization, and diminishing quality of life, in tension with the principle of nonmaleficence. Clinical practice guidelines exist not as rigid constraints, but as ethical guardrails designed to align treatment with demonstrated benefit.6 While immunotherapy is guideline-supported for recurrent or unresectable disease, available trial data predominantly reflect patients with preserved performance status and longer projected survival. Extending these therapies to patients outside those populations without a reasonable expectation of benefit risks blurring the line between individualized care and non-beneficial intervention. Ethical fidelity to evidence requires acknowledging not only what is permissible, but what is prudent. Systemic cancer therapies impose significant financial burdens, including drug costs, insurance copayments, travel requirements, caregiver strain, and opportunity costs.7 For patients with marginal likelihood of benefit, these burdens may compound suffering rather than alleviate it. From a justice perspective, the routine use of costly therapies at the end of life, absent clear benefit, raises concerns about responsible resource stewardship and equity. Ethical care must consider not only access to treatment, but protection from avoidable financial and emotional harm. Palliative medicine offers comprehensive management of pain, dyspnea, dysphagia, anxiety, and existential distress, often achieving outcomes more closely aligned with patient priorities than late-stage disease-directed therapy. In select patients, palliative radiation therapy may also be considered for symptom relief, such as pain, bleeding, or dysphagia, as part of a comprehensive, goal-concordant palliative approach. Transitioning to comfort-focused care is not therapeutic abandonment, but a deliberate ethical choice that prioritizes dignity, symptom relief, and presence. When patients have previously expressed a desire to preserve quality of life, recommending palliation may more faithfully honor their values than introducing interventions with low probability of meaningful benefit. Offering systemic therapy in this context risks fostering therapeutic misconception, the belief that treatment is likely to alter the course of disease meaningfully despite contrary evidence. Ethical communication requires clarity about limits, uncertainty, and prognosis, as well as the moral courage to recommend against interventions that may satisfy a desire to “do something” but fail to serve the patient's best interests.8 Trust in the clinician-patient relationship depends as much on honesty as on technical expertise. Clinicians experience moral distress when asked to provide treatments they believe are unlikely to help and may cause harm. Upholding guideline-concordant palliation supports professional integrity, interdisciplinary cohesion, and sustainable practice. In complex cases such as this, involvement of palliative care specialists and, when appropriate, institutional ethics consultation can help align patient goals, family expectations, and clinical judgment. In patients with advanced HNSCC, poor performance status, and limited life expectancy, guideline-concordant palliation honors nonmaleficence, justice, and fidelity to evidence. It prioritizes comfort over intervention, honesty over false hope, and dignity over escalation. Ethical care at the end of life is not defined by how much treatment is delivered, but by how faithfully care aligns with patient values, clinical realities, and the limits of medicine. Mr R's case illustrates the persistent tension between innovation and restraint in end-of-life oncology. Ethical practice requires that treatment intensity be continuously aligned with the patient's evolving goals, clinical realities, and the limits of available evidence through a shared decision-making process. Whether clinicians ultimately offer disease-directed therapy or recommend exclusive palliation, proportionality, transparency, and respect for patient values must remain central. In complex situations where benefit is uncertain and burdens are substantial, including physical toxicity, financial strain, and emotional cost, early involvement of palliative care can support patients, families, and clinicians alike. When appropriate, institutional ethics consultation can further aid in navigating ethically challenging decisions. Ethical courage lies not only in offering therapy when justified, but also in recognizing when the most humane and professionally responsible act is to recommend comfort-focused care, presence, and relief of suffering. Sholem Hack, conceptualization, drafting of manuscript, literature review, final approval; Ron J. Karni, critical revision for important intellectual content, supervision, final approval. None. None.